Pentadeca Arginate
Also known as: PDA, Pentadecapeptide arginate
Pentadeca Arginate (PDA) is a newer research peptide structurally related to BPC-157, discussed in the context of tissue repair. It is not approved for human use in Australia.
- Category
- Healing & Recovery
- Reported half-life
- Not well established
- Common forms
- Lyophilised powder for reconstitution (research), Grey-market preparations
- Research status
- A newer BPC-157-related research peptide with limited published data. Not approved for human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in early discussion to be of interest for tissue repair and recovery
- Described as structurally related to BPC-157
- Reported to be designed for greater stability via an arginate form
How it is reported to work
Pentadeca Arginate is described as a pentadecapeptide related to BPC-157, prepared as an arginate salt that is proposed to improve stability. Like its relative, it is discussed in connection with tissue-repair signalling pathways. These descriptions are largely preliminary and proposed, with limited formal published research at the time of writing.
Background
Pentadeca Arginate (PDA) is a newer research peptide described as structurally related to BPC-157 and discussed in the context of tissue repair. It is not approved for human use in Australia. This page is educational information, not medical advice, and does not recommend use.
What the research shows
Formal published research on PDA is limited at the time of writing. Claims rest largely on its reported relationship to BPC-157 and preliminary discussion, so reported effects are not established.
| Feature | Reported status |
|---|---|
| Relationship | Related to BPC-157 |
| Formulation | Arginate (reported stability) |
| Australian approval | None |
What people use it for (reported)
Online, PDA is reported to attract interest for recovery and tissue-repair topics, largely by analogy to BPC-157. These are anecdotal reports, not validated outcomes, and should not be read as established facts. Resemblance to a more-studied peptide does not mean that safety or efficacy findings transfer, and the published evidence base for PDA specifically remains thin.
Things to be aware of
PDA is a newer research peptide not approved for human use in Australia, with very limited safety data, and unregulated product identity cannot be verified.
If you have a recovery or health concern, the appropriate step is to consult a qualified healthcare professional. This article does not endorse obtaining or using Pentadeca Arginate.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in early discussion to be of interest for tissue repair and recovery, similar to BPC-157
- Described as structurally related to BPC-157, a peptide associated with healing research
- Reported to be formulated as an arginate salt for greater stability
- Discussed anecdotally in connection with soft-tissue, tendon and gut-related recovery, though claims are not established
Common side effects
- Injection-site reactions such as redness or discomfort reported anecdotally
- Fatigue or light-headedness reported by some users anecdotally
- Mild gastrointestinal upset reported anecdotally
- Effects are poorly characterised given very limited formal data
Rare / serious side effects
- Unknown long-term or serious effects due to absence of controlled human studies
- Reactions to contaminants or impurities from unregulated product
- Allergic or hypersensitivity reactions
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Pentadeca Arginate. Listed so you can make an informed decision, not to suggest any use is safe.
- Self-injection of grey-market product of unverified identity, purity and dose, given the lack of any approved source
- Use of doses extrapolated from BPC-157 anecdotes despite no established dosing for PDA
- Reliance on unproven healing claims in place of appropriate medical care for injuries
- Stacking with other research peptides without any safety data on the combination
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported anecdotally to act over days to weeks like its BPC-157 relative, but onset is not established by formal research.
First effects
anecdotal reports describe early sensations within days
Noticeable change
anecdotal recovery-related reports over a couple of weeks, not established
Clear results
anecdotal claims of fuller recovery over weeks, unverified by research
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Pentadeca Arginate. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection (reported anecdotally; not an approved use) |
|---|---|
| Typical reported dose | Reported anecdotal use is approximately 250-500 mcg per day, following patterns extrapolated from BPC-157; no established or validated dosing exists |
| Frequency | Reported once daily, sometimes split, based on anecdote rather than evidence |
| Cycle length | Anecdotal reports describe cycles of a few weeks; there is no established protocol |
Reported reconstitution (mg → units)
For a reconstituted vial, a 10 mg vial plus 2 mL bacteriostatic water gives 5 mg/mL. A 250 mcg dose is about 0.05 mL, which is roughly 5 units on a 100-unit insulin syringe. Figures are illustrative for an unapproved research peptide.
Work out the units for your vial → CalculatorReported anecdotally as a short daily course over several weeks by analogy to BPC-157, but no validated regimen exists. This is reported information about an unapproved research peptide, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
Pentadeca Arginate is a newer research peptide not approved for human use in Australia, and there is very limited safety data on it. Product identity and purity from unregulated sources cannot be verified. Anyone with a recovery or health concern should consult a qualified healthcare professional.